Ellis Investment Partners LLC Has $43,000 Stock Holdings in GlaxoSmithKline plc (NYSE:GSK)

Ellis Investment Partners LLC raised its holdings in shares of GlaxoSmithKline plc (NYSE:GSK) by 144.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,022 shares of the pharmaceutical company’s stock after purchasing an additional 604 shares during the quarter. Ellis Investment Partners LLC’s holdings in GlaxoSmithKline were worth $43,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Geode Capital Management LLC boosted its stake in GlaxoSmithKline by 12.9% during the 4th quarter. Geode Capital Management LLC now owns 424,397 shares of the pharmaceutical company’s stock valued at $16,216,000 after acquiring an additional 48,476 shares during the last quarter. First Trust Advisors LP boosted its stake in GlaxoSmithKline by 14.6% during the 1st quarter. First Trust Advisors LP now owns 714,614 shares of the pharmaceutical company’s stock valued at $29,864,000 after acquiring an additional 90,928 shares during the last quarter. Rockefeller Capital Management L.P. bought a new position in GlaxoSmithKline during the 1st quarter valued at $373,000. OppenheimerFunds Inc. boosted its stake in GlaxoSmithKline by 6.0% during the 1st quarter. OppenheimerFunds Inc. now owns 521,890 shares of the pharmaceutical company’s stock valued at $21,810,000 after acquiring an additional 29,473 shares during the last quarter. Finally, Burney Co. boosted its stake in GlaxoSmithKline by 21.5% during the 1st quarter. Burney Co. now owns 8,017 shares of the pharmaceutical company’s stock valued at $335,000 after acquiring an additional 1,419 shares during the last quarter. 11.12% of the stock is owned by institutional investors and hedge funds.

A number of research firms have commented on GSK. ValuEngine downgraded shares of GlaxoSmithKline from a “hold” rating to a “sell” rating in a research note on Tuesday, September 10th. Societe Generale upgraded shares of GlaxoSmithKline from a “sell” rating to a “buy” rating in a research note on Tuesday, September 3rd. Jefferies Financial Group reiterated a “buy” rating on shares of GlaxoSmithKline in a research note on Thursday, August 29th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of GlaxoSmithKline in a research note on Tuesday, August 13th. Finally, Morgan Stanley restated an “underweight” rating on shares of GlaxoSmithKline in a research report on Monday, June 17th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and three have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $41.79.



In other news, Director Plc Glaxosmithkline acquired 177,777 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The shares were purchased at an average cost of $45.00 per share, for a total transaction of $7,999,965.00. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 10.00% of the company’s stock.

Shares of GlaxoSmithKline stock traded up $0.08 during trading hours on Thursday, reaching $42.16. The company’s stock had a trading volume of 32,458 shares, compared to its average volume of 2,271,674. The company’s 50 day simple moving average is $41.60 and its 200 day simple moving average is $40.76. The company has a debt-to-equity ratio of 7.86, a quick ratio of 0.48 and a current ratio of 0.71. GlaxoSmithKline plc has a one year low of $36.41 and a one year high of $43.22. The stock has a market cap of $104.96 billion, a P/E ratio of 13.33, a price-to-earnings-growth ratio of 2.02 and a beta of 0.68.

GlaxoSmithKline (NYSE:GSK) last posted its quarterly earnings results on Wednesday, July 24th. The pharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.64 by $0.14. GlaxoSmithKline had a net margin of 13.84% and a return on equity of 175.45%. The company had revenue of $10.04 billion for the quarter, compared to the consensus estimate of $9.55 billion. On average, sell-side analysts predict that GlaxoSmithKline plc will post 2.96 earnings per share for the current fiscal year.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Recommended Story: Average Daily Trade Volume Explained

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.